Darren R. Feldman

16.3k total citations · 2 hit papers
252 papers, 6.0k citations indexed

About

Darren R. Feldman is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Darren R. Feldman has authored 252 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Surgery, 127 papers in Pulmonary and Respiratory Medicine and 87 papers in Molecular Biology. Recurrent topics in Darren R. Feldman's work include Testicular diseases and treatments (125 papers), Renal cell carcinoma treatment (75 papers) and Renal and related cancers (49 papers). Darren R. Feldman is often cited by papers focused on Testicular diseases and treatments (125 papers), Renal cell carcinoma treatment (75 papers) and Renal and related cancers (49 papers). Darren R. Feldman collaborates with scholars based in United States, Canada and United Kingdom. Darren R. Feldman's co-authors include Robert J. Motzer, Sujata Patil, George J. Bosl, Martin H. Voss, Joel Sheinfeld, Michelle S. Ginsberg, Nicole Ishill, Hani Hassoun, Toni K. Choueiri and Daniel J. George and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Journal of Clinical Oncology.

In The Last Decade

Darren R. Feldman

237 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

2017 507 citations Toni K. Choueiri, Susan Halabi et al. Journal of Clinical Oncology profile →
Testicular cancer

2018 302 citations Peter Albers, Darren R. Feldman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Darren R. Feldman United States	39	2.9k	2.4k	2.4k	1.6k	1.2k	252	6.0k
Pierre Kerbrat France	42	2.1k 0.7×	1.1k 0.5×	2.4k 1.0×	4.6k 2.8×	1.9k 1.6×	189	8.3k
Federica Perrone Italy	50	2.7k 1.0×	2.1k 0.9×	2.0k 0.9×	3.6k 2.2×	1.3k 1.1×	235	7.9k
Maurizio Martini Italy	44	1.1k 0.4×	2.3k 1.0×	1.0k 0.4×	1.9k 1.2×	1.3k 1.1×	281	6.5k
Michael Bamberg Germany	45	2.3k 0.8×	1.3k 0.5×	1.3k 0.6×	1.0k 0.6×	722 0.6×	179	6.9k
Ignacio Durán Spain	37	1.4k 0.5×	1.5k 0.6×	1.6k 0.7×	2.3k 1.4×	562 0.5×	206	4.8k
Frank Saran United Kingdom	34	1.8k 0.6×	1.2k 0.5×	827 0.4×	852 0.5×	985 0.8×	149	6.2k
Vaia Vlamis United States	28	1.6k 0.6×	750 0.3×	1.8k 0.7×	1.0k 0.6×	384 0.3×	36	4.1k
Heinz Schmidberger Germany	33	2.3k 0.8×	1.3k 0.5×	4.3k 1.8×	5.5k 3.4×	944 0.8×	249	9.1k
Jonathan Shamash United Kingdom	30	1.5k 0.5×	698 0.3×	937 0.4×	981 0.6×	425 0.4×	141	3.1k
J.T. Roberts United Kingdom	29	1.3k 0.4×	1.1k 0.5×	4.3k 1.8×	1.5k 0.9×	276 0.2×	102	5.9k

Countries citing papers authored by Darren R. Feldman

Since Specialization

Citations

This map shows the geographic impact of Darren R. Feldman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darren R. Feldman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darren R. Feldman more than expected).

Fields of papers citing papers by Darren R. Feldman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darren R. Feldman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darren R. Feldman. The network helps show where Darren R. Feldman may publish in the future.

Co-authorship network of co-authors of Darren R. Feldman

This figure shows the co-authorship network connecting the top 25 collaborators of Darren R. Feldman. A scholar is included among the top collaborators of Darren R. Feldman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darren R. Feldman. Darren R. Feldman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pal, Sumanta K., Thomas Powles, Ravindran Kanesvaran, et al.. (2025). STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma. Future Oncology. 21(7). 787–794. 1 indexed citations

Kerns, Sarah L., Paul C. Dinh, Patrick O. Monahan, et al.. (2025). Factors associated with longitudinal progression of the cumulative burden of morbidity and overall mortality after cisplatin-based chemotherapy for testicular cancer. JNCI Journal of the National Cancer Institute. 117(9). 1797–1808. 1 indexed citations

Matulewicz, Richard S., Andrea Knežević, Brandon Williams, et al.. (2025). Comparison of serum and plasma microRNA expression levels in patients with germ cell tumours. British Journal of Urology. 135(5). 748–750.

Fitzgerald, Kelly N., Chung‐Han Lee, Martin H. Voss, et al.. (2024). Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial. European Urology. 86(2). 90–94. 15 indexed citations

Tateo, Valentina, Scott M. Gilbert, Victoria K. Cortessis, et al.. (2024). Epidemiology and Risk Factors for Testicular Cancer: A Systematic Review. European Urology. 87(4). 427–441. 9 indexed citations

Hoyt, Michael A., Jennifer S. Cheavens, Michael Daneshvar, et al.. (2023). Goal-Focused Emotion-Regulation Therapy (GET) in Young Adult Testicular Cancer Survivors: A Randomized Pilot Study. Annals of Behavioral Medicine. 57(9). 777–786. 6 indexed citations

Sanchez, Victoria A., Megan M. Shuey, Paul C. Dinh, et al.. (2023). Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy. Journal of Clinical Oncology. 41(12). 2211–2226. 23 indexed citations

Kotecha, Ritesh R., Andrea Knežević, Kanika Arora, et al.. (2023). Genomic ancestry in kidney cancer: Correlations with clinical and molecular features. Cancer. 130(5). 692–701. 5 indexed citations

Dinh, Paul C., Patrick O. Monahan, Sophie D. Fosså, et al.. (2023). Impact of pain and adverse health outcomes on long-term US testicular cancer survivors. JNCI Journal of the National Cancer Institute. 116(3). 455–467. 7 indexed citations

10.

Trendowski, Matthew R., Emma Wilkinson, Paul C. Dinh, et al.. (2022). Pharmacogenomics of cisplatin‐induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. Cancer Medicine. 11(14). 2801–2816. 11 indexed citations

11.

Wibmer, Andreas G., Paul C. Dinh, Lois B. Travis, et al.. (2022). Associations of Body Fat Distribution and Cardiometabolic Risk of Testicular Cancer Survivors After Cisplatin-Based Chemotherapy. JNCI Cancer Spectrum. 6(4). 8 indexed citations

12.

Trendowski, Matthew R., Heather E. Wheeler, Darren R. Feldman, et al.. (2020). Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. Clinical Cancer Research. 26(24). 6550–6558. 9 indexed citations

13.

Albany, Costantine, Lawrence H. Einhorn, Lawrence Garbo, et al.. (2017). Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases. The Oncologist. 23(3). 316–323. 40 indexed citations

14.

Dolan, M. Eileen, Heather E. Wheeler, Eric R. Gamazon, et al.. (2017). Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer. Clinical Cancer Research. 23(19). 5757–5768. 63 indexed citations

15.

Choueiri, Toni K., Susan Halabi, Ben L. Sanford, et al.. (2017). Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. Journal of Clinical Oncology. 35(6). 591–597. 507 indexed citations breakdown →

16.

Fung, Chunkit, Howard D. Sesso, AnnaLynn M. Williams, et al.. (2017). Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy. Publisher. 1 indexed citations

17.

Bastos, Diogo Assed, Ana M. Molina, Vaios Hatzoglou, et al.. (2014). Safety and Efficacy of Targeted Therapy for Renal Cell Carcinoma With Brain Metastasis. Clinical Genitourinary Cancer. 13(1). 59–66. 30 indexed citations

18.

Feldman, Darren R., Wendy Schaffer, & Richard M. Steingart. (2012). Late Cardiovascular Toxicity Following Chemotherapy for Germ Cell Tumors. Journal of the National Comprehensive Cancer Network. 10(4). 537–544. 48 indexed citations

19.

Dhodapkar, Kavita M., Darren R. Feldman, Soroosh Radfar, et al.. (2010). Natural immunity to pluripotency antigen OCT4 in humans. Proceedings of the National Academy of Sciences. 107(19). 8718–8723. 68 indexed citations

20.

Feldman, Darren R., Joel Sheinfeld, Dean F. Bajorin, et al.. (2010). TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis. Journal of Clinical Oncology. 28(10). 1706–1713. 147 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact